secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seagen Inc. (—)
CIK:        0001060736
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-294938
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer completes $229.00/share acquisition of Seagen; Seagen delisted from Nasdaq
--------------------------------------------------------------------------------

- Merger closed December 14, 2023; Seagen becomes wholly owned subsidiary of Pfizer.
- Each Seagen common share converted into the right to receive $229.00 in cash.
- Seagen common stock ceased trading and will be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting.
- All prior directors and named executive officers (CEO, CFO, etc.) ceased; new directors and President appointed by Pfizer.
- Seagen charter and bylaws amended and restated in connection with the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/0001193125-23-294938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1060736/000119312523294938/d557257d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-294938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer